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Histopathologic features of breast cancer such as tumour size, grade and axillary lymph node (LN) status variably reflect tumour
biology and time. Recent evidence suggests that the biological character of breast cancer is established at an early stage and has a
major impact on clinical course. The aim of this study was to distinguish the impact of biology on breast cancer histopathology by
comparing features of breast cancers diagnosed following population mammographic screening with prevalent vs incident detection
and screening interval. Central histopathology review data from 1147 cases of ductal in situ and/or invasive breast cancer were
examined. Size, grade and LN status of invasive cancers were positively correlated (Po0.001). Prevalent invasive cancers were larger
(Po0.001) and more likely to be LN positive (P¼0.02) than incident cases, but grade was not associated with screening episode
(P¼0.7). Screening interval for incident cancers was positively associated with invasive cancer size (P¼0.05) and LN status
(P¼0.002) but not grade (P¼0.1). Together, these data indicate that biology and time both impact on size and LN status of invasive
breast cancer, but grade reflects biology alone. In view of the clinical importance of breast cancer biology, grade as its most direct
indicator assumes particular significance.
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Histopathologic assessment of breast cancer has long provided the
basis for prediction of recurrence risk and prescription of adjuvant
therapy. The features routinely documented include tumour size,
type, grade and the presence of axillary lymph node (LN)
metastases (Australian Cancer Network, 2001). In addition,
presence of oestrogen and progesterone receptors (ERa and PR)
is assessed principally to indicate the potential value of endocrine
therapy (Elledge et al, 2000).
Recently, gene expression studies, which combine data on
expression of thousands of genes with powerful computational
analysis, have given new insight into breast cancer biology. In
particular, these studies have demonstrated that subtypes of breast
cancer with a predictable clinical course can be defined and
reproducibly identified on the basis of gene expression patterns
(Sorlie et al, 2001, 2003; van de Vijver et al, 2002; van’t Veer et al,
2002). In this is a compelling demonstration that tumour biology
has a pervasive impact on clinical outcome. Furthermore, evidence
that the essential biological character of breast cancer is apparent
early in disease development comes from the detection of the same
discriminant gene expression profiles in early-stage breast cancer,
more advanced lesions and metastases (van de Vijver et al, 2002;
Ma et al, 2003; Ranaswamy et al, 2003).
In common with global gene expression patterns, the histo-
pathologic features of breast cancer reflect the influence of a
number of biological processes including not only those operating
in cancer cells but also cancer–stromal interactions and complex
immune and hormonal influences. However, in addition to
biology, the histopathology ‘snapshot’ of a cancer incorporates
the period of opportunity that morphological features have had to
develop. In the light of recent revelations on the natural history
and clinical importance of breast cancer biology, it is timely to
consider how biology is reflected in histopathologic parameters.
Population mammographic screening, effecting preclinical
detection and regular re-examination, provides an opportunity to
examine the relative contribution of biology and time to
development of the major histopathologic features of breast
cancer. We have examined this issue in a large cohort of screen
detected breast cancers that were subject to central histopathology
review. Pathologic features of breast cancer diagnosed at a first
screening round (prevalent) were compared with incident cases on
the basis that prevalent cancers have potentially longer to develop
prior to detection than incident cancers where this is theoretically
limited by screening interval. In addition, for incident invasive
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interval between the diagnostic screening round and the previous
negative screen.
PATIENTS AND METHODS
Patient cohort
Patients were women diagnosed with breast cancer, as a con-
sequence of mammographic screening, by the BreastScreen Greater
Western Sydney unit in New South Wales Australia, in the period
from the commencement of the screening programme in 1993 to
February 2000. In this period, 1519 women were diagnosed with
invasive breast cancer or ductal carcinoma in situ (DCIS) that was
subsequently confirmed in an excision specimen. At the time of
analysis, cancers from 1159 of these individuals had been subject
to central histopathology review. This group forms the study
cohort following further exclusion of 11 patients with recurrent
breast cancer, six with interval cancer and three with review data
unavailable. In the final study cohort, cases of simultaneously
diagnosed bilateral breast cancer were included as two separate
cancers (n¼8). In patients with multiple foci of cancer in the same
breast (n¼43), only features of the largest lesion were included.
Hence, data from 1147 separate cancers in 1139 patients were
analysed: 977 invasive cancers (including 572 with coexisting
DCIS) and 170 cases of DCIS only.
Information on patient age and screening round of diagnosis
was derived from the records of BreastScreen Greater Western
Sydney. In general, following an initial screen, women are invited
to attend for rescreening at intervals of 21–27 months (270.25
years), except that annual screens are offered to individuals with a
clinical indicator of increased breast cancer risk detected at
screening, or who have a first-degree relative with a history of
breast cancer. Individuals who choose not to attend for rescreening
at invitation may present for rescreening at any subsequent time.
Any mammograms taken for screening or other purposes outside
the operations of the BreastScreen Greater Western Sydney
screening unit were not taken account of in this analysis.
Cancers diagnosed at the initial screening episode were
designated prevalent. Cancers diagnosed at a round subsequent
to one or more screens where cancer was not detected were
incident.
Pathology review
Central pathology review was conducted at the Institute for
Clinical Pathology and Medical Research (ICPMR), Westmead
Hospital. Original pathology reports and slides from a number of
regional laboratories were examined by senior pathologist trainees
under the supervision of a single experienced breast pathologist
(AMB). Histopathological features were documented according to
a standardised format and included: invasive cancer size, type,
grade (Elston and Ellis, 1991), and the number and status of
excised axillary LNs. In 479 of 742 (65%) cases that were DCIS only
or DCIS associated with invasive cancer, one or more DCIS grades
was assigned according to the options: high grade (comedo),
intermediate grade, low grade (noncomedo) or mixed nuclear
grades.
This project received institutional Human Research Ethics
Committee approval.
Statistical analysis
Statistical analyses were performed using SPSS for Windows
Version 12.0 (SPSS Science, Chicago, US). Tumour size, LN status
and screening interval were categorised in most analyses as shown
in relevant figures and tables referred to in the text. Tumour size
and screening interval were compared both as continuous and
categorical variables. Pearson’s w
2 test (or Fisher’s exact test if an
expected cell size o5) was used to test for association between
categorical variables. Spearman’s rank correlation (r) was used to
quantify the degree of association between ordered categorical
variables or continuous variables. Multiple logistic regression
analysis was used to test for interaction between the effects of
episode type and histopathological grade on LN positivity. A
general linear model was used to test for interaction between the
effects of grade and episode type on tumour size. P-values p0.05
were considered to be statistically significant.
RESULTS
Patient and tumour characteristics
Patient and tumour characteristics are summarised in Table 1.
In this cohort, accrued from the commencement of a population
mammographic screening programme, 699 (61%) cancers were
prevalent and 446 (39%) incident. The majority of incident cancers
were diagnosed at screening rounds 2 (n¼256, 57.4%) and
3( n¼152, 34.1%), with the remaining small proportion diagno-
sed at rounds 4–6 (n¼38, 8.5%). The age at diagnosis ranged
from 40.1 to 92.6 years (median 59.9). This was similar to the age at
first screen for the cohort (40.1–92.6, median 58.7 years),
reflecting the high proportion of cases diagnosed at the first
screening round.
The predominant histological type of invasive cancers was
ductal not otherwise specified (83.3%). The overall distribution of
invasive cancer grades was 39.9% grade 1, 39% grade 2 and 21.1%
grade 3. The majority of invasive cancers were of relatively small
size with 37.8% p10mm in maximum dimension and 83.4%
p20mm. Most invasive cancers were axillary LN negative (72.5%).
There were 170 reviewed cases consisting entirely of DCIS. In
105 of these graded according to the schema outlined in Table 1,
57.1% were designated high grade (comedo) or a combination of
grades including high grade (comedo).
Inter-relationship of histopathological features of invasive
cancer
The histopathological features of invasive breast cancer were
positively correlated such that higher grade was associated with
larger tumour size (P¼0.001, r¼0.31, Figure 1A) and axillary LN
metastases (Po0.001, r¼0.14, Figure 1B). Larger tumour size was
also related to the presence of LN metastases (Po0.001, r¼0.35,
Figure 1C). Where DCIS was coexistent with invasive cancer, and a
single uniform DCIS grade was recorded, this was significantly
correlated with the invasive cancer grade (Po0.001, r¼0.70,
n¼273, Figure 1D).
Pathological features of invasive cancer and diagnostic
screening episode
Prevalent invasive breast cancers were on the whole larger
(Po0.001) and more commonly LN positive than incident cases
(P¼0.02). In contrast, the distribution of invasive cancer grades
was not different between prevalent and incident detected cancers
(P¼0.7, Table 2A).
The association between diagnostic screening episode and
invasive cancer size was independent of grade (P¼0.1). When
LN status was considered in relation to both invasive cancer grade
and episode type, the demonstrated association between LN
positivity and prevalent screening round appeared strongest for
lower-grade cancers. However, this distinction was not statistically
significant (grade by episode-type interaction for LN status P¼0.1,
Table 2B).
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For incident cases, the interval between the diagnostic screening
round and the previous negative screen (screening interval) ranged
from 0.9 to 5.4 years with a median interval of 2.0 years. Screening
interval for the majority of cases was consistent with the usual
recommended screening interval of 270.25 years: the 25 to 75
percentile range for screening interval was 2.0–2.1 years and
screening interval was equivalent to the median of 2.0 years for
over 40% of cases. A screening interval of 1 year or less was
recorded for 9% of cases. Conversely, 6% of cases had a screening
interval longer than 2.5 years (Figure 2A).
Table 1 Patient and tumour characteristics
n (%)
All cancers 1147
Invasive cancer 977 (85.2)
Invasive cancer+DCIS 572
DCIS only 170 (14.8)
Episode type (n¼1145
a)
Prevalent 699 (61.0)
Incident 446 (39.0)
Age at first screen
Range (median) 40.1–92.6 (58.7)
Age at diagnosis
Range (median) 40.1–92.6 (59.9)
Invasive cancers 977
Histological type
Ductal NOS 814 (83.3)
Invasive lobular, classical 47 (4.8)
Tubular carcinoma 35 (3.6)
Mucinous carcinoma 29 (3.0)
Invasive lobular, variant 20 (2.0)
Other/mixed 32 (3.3)
Grade (n¼944
b)
1 377 (39.9)
2 368 (39.0)
3 199 (21.1)
Tumour size (mm) (n¼949
c)
p5 83 (8.8)
45–p10 275 (29.0)
410–p20 433 (45.6)
420–p50 152 (16.0)
450 6 (0.6)
LN positive (n¼829
d)
0 601 (72.5)
1–4 166 (20.0)
44 62 (7.5)
DCIS+invasive cancer
Histological type
e 374
f
Low grade (noncomedo) 81 (21.7)
Intermediate grade 135 (36.1)
High grade (comedo) 129 (34.5)
Ductal – mixed nuclear grades 29 (7.8)
Pure DCIS
Histological type
e 105
g
Low grade (noncomedo) 9 (8.5)
Intermediate grade 29 (27.6)
High grade (comedo) 60 (57.1)
Ductal – mixed nuclear grades 7 (6.7)
DCIS¼ductal carcinoma in situ;L N¼lymph nodes; NOS¼not otherwise specified.
aData not available for two cases.
bTumours too small to grade (n¼13), grade not
recorded (n¼20).
cSize was not recorded at review (n¼28).
dLNs were not
removed or not reviewed (n¼148).
eCases with more than one DCIS histological
type recorded are included in the highest grade category: n¼67 for DCIS with
invasive cancer (n¼56 included as intermediate grade and n¼11 as high grade) and
n¼23 for the pure DCIS group (n¼18 included as intermediate grade and n¼5a s
high grade).
f,gExcludes 198 and 65 cases not graded according to this scheme.
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Figure 1 (A–D) Inter-relationship of histopathologic features of
invasive breast cancer: (A) Grade vs tumour size n¼921 (y-axis: % of
each grade category), Po0.001, r¼0.31. (B) Grade vs LN status n¼810
(y-axis: % of each grade category), Po0.001, r¼0.14. (C) LN status vs
tumour size n¼811 (y-axis: % of each LN category), Po0.001, r¼0.35.
(D) Invasive cancer grade vs DCIS grade. Only cases with DCIS grade
designated solely as low grade (noncomedo), intermediate grade or high
grade (comedo) were included in this analysis n¼273 (y-axis: % of each
invasive cancer grade category), Po0.001, r¼0.7. Abbreviations: LN,
lymph node.
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screening interval
There was a weak but significant positive correlation between
screening interval and incident invasive breast cancer size
(P¼0.05, r¼0.10 for screening interval and size as continuous
variables, P¼0.03 for categories as shown in Figure 2B). The
relationship between screening interval and tumour size was
independent of grade (P¼0.9).
The presence and number of axillary LN metastases was also
positively associated with screening interval (P¼0.002, Figure 2C).
There was no statistically significant association between grade
and screening interval category (P¼0.1, Figure 2D).
DISCUSSION
In this study, influence of the period of development of invasive
breast cancer prior to diagnosis was judged by comparing
prevalent screen detected cancers with incident cases and also by
examining the effect of screening interval on features of incident
cases. Clearly, the size of breast cancer increases with time and
inferences about time inherent in this analysis are supported by
our finding that prevalent cancers were generally larger than
incident cases and size of invasive cancers was positively
correlated with screening interval. Histopathologic grade was not
related to diagnostic screening round or screening interval which,
in combination with the correlation between grade of in situ and
invasive disease, supports the conclusion that grade is not
influenced by time but directly reflects cancer biology. Invasive
cancer size and LN status were each strongly correlated with grade
in addition to being related to diagnostic screening round and
screening interval, consistent with a combined influence of biology
and time on these features.
These findings give insight into the demonstration that a
prognostic gene expression signature in breast cancer correlated
strongly with grade, less strongly with tumour size and was not
related to axillary LN status (van de Vijver et al, 2002), since the
impact of biology on these later two features is time dependent.
Furthermore, a unifying hypothesis to explain the apparent
paradox of failure of a direct relationship between the prognostic
gene expression signature and LN status given the well-established
prognostic significance of axillary LN metastases (Elston et al,
1999; Singletary et al, 2002) may be that the end points of LN
positivity and clinical outcome are each determined by biology and
time, but the impact of time on each of these is variable, dependent
on biology and not necessarily equal (Figure 3).
To generate a prognostic gene expression signature, a large
number of biological indicators are revealed, and then ranked
according to their combined ability to discriminate between cases
that relapse and those that do not (van’t Veer et al, 2002). This is
an essentially different process than was used to establish current
clinicopathologic prognostic indicators. Interestingly, many of the
biological pathways that have emerged as influential in discrimi-
native gene sets, such as hormone receptor activation and cellular
proliferation (van’t Veer et al, 2002; Gruvberger et al, 2003), have
long been known to be important in distinguishing different types
of breast cancer and are routinely assessed. However, the superior
prognostic power of gene expression studies suggests that
prediction of clinical course using commonly available clinico-
pathological parameters could be improved. In this regard, it is
necessary to discern the influence of biology in histopathological
features and the variable influence of time on tumour size and LN
status is important to acknowledge.
A potential weakness of histopathologic assessment of breast
cancer is the influence of interobserver variability on the features
reported. In the presented cohort, this effect is reduced because
data were derived from central review of diagnostic material.
Another general limitation of breast cancer histopathology
reporting is the absence of a robust, universally accepted method
for grading DCIS (Consensus Conference Committee, 1997). In the
current report, an overall descriptive assessment of DCIS grade
was recorded, and notwithstanding the limitations of this
approach, a strong correlation between the grade of DCIS and
concomitant invasive cancer was found, which is consistent with
previous reports (Gupta et al, 1997; Leong et al, 2001) and data
from cytogenetic studies showing distinct patterns of chromoso-
mal aberration in low- and intermediate-grade invasive cancer and
DCIS of the same grades (Buerger et al, 1999a,b, 2001).
The presented cohort of screen detected breast cancers was
accrued from the beginning of a population screening programme
and selected on the basis of completed central histopathology
review. Despite this, the overall histopathologic features of the
cohort are typical of screen detected invasive breast cancer, which
has been repeatedly demonstrated to be generally smaller, lower
grade and less likely to be LN positive than cancers presenting
clinically (Cowan et al, 1997; Ernst et al, 2002; Vacek et al, 2002).
Diagnosis of breast cancer at an early stage is the principal aim
of mammographic screening and the relatively small size and low
rate of LN positivity in screen detected cancers demonstrates this
effect. However, as grade is a time-independent indicator of
biology, the overall lower grade of screen detected invasive cancers
indicates an additional more complex interaction between screen-
ing diagnosis and breast cancer biology. This preferential detection
of lower-grade cancers is consistent with the ‘length bias’ inherent
in population cancer screening, whereby cancers that progress
slowly are preferentially detected as these have a longer preclinical
period amenable to screen diagnosis (‘sojourn time’) (Cole and
Morrison, 1980; IARC, 2002). Conversely aggressive, rapidly
progressing cancers are more likely to reach the threshold for
clinical detection before a patient presents for screening or in the
interval between routine screens and will therefore be reduced in a
screen detected cancer cohort. In our data set, indirect support for
an impact of length bias on the distribution of invasive cancer
grades comes from DCIS-only cases, which are unlikely to be
diagnosed clinically, and which showed a proportion of high-grade
cases (57.1%) that was greater than high-grade invasive cancers
Table 2 Relationship between histopathological features of invasive
cancers and diagnostic screening episode. (A) Episode type by tumour size,
LN status and grade and (B) proportion LN positive by grade and episode
type
Prevalent, n (%) Incident, n (%)
(A)
a
Tumour size (mm) (n¼948)
p10 182 (31.4) 175 (47.4) Po0.001
410–p20 288 (49.8) 145 (39.3)
420 109 (18.8) 49 (13.3)
LNs (n¼829)
Negative 355 (69.6) 246 (77.1) P¼0.02
Positive 155 (30.4) 73 (22.9)
Grade (n¼943)
1 226 (38.9) 150 (41.4) P¼0.7
2 233 (40.1) 135 (37.3)
3 122 (21.0) 77 (21.3)
(B)
b
Grade Proportion LN positive
1 46/182 (25.3) 16/118 (13.6) P¼0.1
2 70/204 (34.3) 32/121 (26.4)
3 39/113 (34.5) 24/72 (33.3)
LN¼lymph nodes.
aP-values from Pearson w
2 test.
bP-value represents grade by
episode-type interaction tested using multiple logistic regression analysis of LN
positivity.
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invasive cancers in a population not selected by detection method
(47%) (Elston and Ellis, 1991).
According to population cancer screening theory, ‘length bias’ is
greatest at the prevalent screening round and may be almost
eliminated by the third screening round if the screening interval is
short (Cole and Morrison, 1980). If length bias is eliminated, this
theory predicts a greater proportionate representation of aggres-
sive fast-growing cancers among incident cases. However, in our
cohort, the overall larger size of prevalent cancers compared with
incident cases argues against a loading of rapidly progressing cases
in the later group. The apparent persistence of length bias among
incident invasive cancers in this cohort may be attributable to the
fact that the majority (57.4%) of incident cases were detected at
the second screening round. It is also possible that overall the
screening interval was not sufficiently short relative to sojourn
time of rapidly progressing cancers to eliminate the effect of length
bias for the entire cohort.
The advantages of this study compared with previous analyses
of screen detected breast cancer pathology are not only the large
cohort size and central review format but also data from
contemporary research, in particular gene expression studies, that
give fresh insight into the results. Rational interpretation of
histopathologic features of breast cancer is especially important in
the era of population mammographic screening as cancers with
disparate biology may similarly present as small and LN negative.
In the light of new knowledge about the importance of tumour
biology, grade as its most direct histopathologic indicator assumes
particular significance.
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interval and invasive breast cancer size, represented as a proportion of each screening interval category n¼369, P¼0.03. (C) Comparison between
screening interval and axillary LN status, represented as a proportion of each screening interval category n¼319, P¼0.002. (D) Comparison between
screening interval and invasive cancer grade, represented as a proportion of each screening interval category n¼362, P¼0.1. Abbreviations: LN, lymph
node.
Clinical 
outcome 
LN
metastasis
Tumour 
biology Time
Figure 3 Schematic representation of the disparate influence of time
and breast cancer biology on clinical indicators and end points.
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